Brief: Shattuck Labs Says Sl-172154 Demonstrated A Manageable Interim Safety Profile In Combination With Aza
14/06/2024 12:34
June 14 (Reuters) - Shattuck Labs Inc STTK.O :
* SHATTUCK LABS INC - SL-172154 DEMONSTRATED A MANAGEABLE
INTERIM
SAFETY PROFILE IN COMBINATION WITH AZA -
* SHATTUCK LABS INC - OBSERVED 67% OBJECTIVE RESPONSE RATE
(ORR)
IN FRONTLINE HR-MDS PATIENTS, PRIMARILY WITH TP53 MUTATIONS
* SHATTUCK LABS INC - OBSERVED 43% ORR IN FRONTLINE TP53M
AML
PATIENTS
Source text for Eikon: ID:nGNXbxcQCT
Further company coverage: STTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shattuck Labs
See all newsBrief: Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development
Shattuck Labs Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health